Brian Stuglik, Verastem CEO
May 30, 2023 07:46 AM EDTUpdated June 3, 06:12 PM
R&D

Ve­rastem touts mid-stage da­ta in rare type of ovar­i­an can­cer: #AS­CO23

Lei Lei Wu

News Reporter

Ve­rastem says its drug com­bi­na­tion led to re­spons­es in near­ly half of pa­tients with a rare type of ovar­i­an can­cer that grows slow­ly but is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times